Value of P-selectin in the prognosis of cardiovascular events in patients with multiple myeloma
DOI:
https://doi.org/10.14739/2409-2932.2022.2.259829Keywords:
P-selectin, cardiovascular events, multiple myeloma, survival, prognosisAbstract
Multiple myeloma (MM) survival has greatly improved in recent decades. MM is usually diagnosed in elderlies. Patients do not necessarily die from MM, so cardiovascular health may be a key factor threatening long-term survival.
The aim of the research: to evaluate the prognostic value of circulating P-selectin for cardiovascular events in patients with multiple myeloma in full or partial remission.
Materials and methods. 97 patients with MM with complete or partial remission were enrolled in the study. None of the patients had received any lipid-modulating medications, including statins or fibrates, before enrollment. The observation period was up to 1 year. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of P-selectin was used.
Results. During the observation period progression of MM was proved in 25 patients, 5 persons were excluded for poor follow-up. 67 patients were included in the statistical analysis. Thirty-six cumulative clinical events occurred in 18 patients (26.9 %) within the follow-up, with their distribution being as follows: 2 cardiovascular deaths, 16 cardiac arrhythmias, 3 cardiac ischemic events, 1 stroke, 4 chronic heart failures, and 10 hospital admissions for cardiovascular reasons. 2 deaths were not related with cardiovascular pathology. Medians of circulating levels of P-selectin in free-events subject cohort and subjects cohort with cardiovascular events were 58.24 ng/ml (95 % confidence interval (CI) = 32.27–77.48 ng/ml) and 87.57 ng/ml (95 % CI = 51.12–114.89 ng/ml) (Р < 0.01). In multivariate logistic regression circulating P-selectin independently predicted cumulative cardiovascular events (odds ratio (OR) = 1.11; 95 % CI = 1.08–1.15; Р = 0.02) in patients after sever coronavirus disease (COVID-19) within 1 year of observation period.
Conclusions. Among patients with documented multiple myeloma in remission increased circulating P-selectin was associated with increased cumulative cardiovascular events.
References
Rajkumar, S. V. (2011). Treatment of multiple myeloma. Nature Reviews Clinical Oncology, 8(8), 479-491. https://doi.org/10.1038/nrclinonc.2011.63
Al-Kindi, S. G., & Oliveira, G. H. (2016). Prevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer. Mayo Clinic Proceedings, 91(1), 81-83. https://doi.org/10.1016/j.mayocp.2015.09.009
Kazandjian, D. (2016). Multiple myeloma epidemiology and survival: A unique malignancy. Seminars in Oncology, 43(6), 676-681. https://doi.org/10.1053/j.seminoncol.2016.11.004
Austin, P. C., Lee, D. S., & Fine, J. P. (2016). Introduction to the Analysis of Survival Data in the Presence of Competing Risks. Circulation, 133(6), 601-609. https://doi.org/10.1161/circulationaha.115.017719
Smith, B. A. H., & Bertozzi, C. R. (2021). The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. Nature Reviews Drug Discovery, 20(3), 217-243. https://doi.org/10.1038/s41573-020-00093-1
Grobler, C., Maphumulo, S. C., Grobbelaar, L. M., Bredenkamp, J. C., Laubscher, G. J., Lourens, P. J., Steenkamp, J., Kell, D. B., & Pretorius, E. (2020). Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. International Journal of Molecular Sciences, 21(14), 5168. https://doi.org/10.3390/ijms21145168
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018). Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal, 39(30), 2780-2792. https://doi.org/10.1093/eurheartj/ehy301
Song, C., Wu, G., Chang, S., & Bie, L. (2020). Plasma P-selectin level is associated with severity of coronary heart disease in Chinese Han population. Journal of International Medical Research, 48(6), 030006051989643. https://doi.org/10.1177/0300060519896437
Shen, L., Yang, T., Xia, K., Yan, Z., Tan, J., Li, L., Qin, Y., & Shi, W. (2020). P-selectin (CD62P) and soluble TREM-like transcript-1 (sTLT-1) are associated with coronary artery disease: a case control study. BMC Cardiovascular Disorders, 20(1). https://doi.org/10.1186/s12872-020-01663-2
Nguyen, S. D., Korhonen, E. A., Lorey, M. B., Hakanpää, L., Mäyränpää, M. I., Kovanen, P. T., Saharinen, P., Alitalo, K., & Öörni, K. (2021). Lysophosphatidylcholine in phospholipase A2-modified LDL triggers secretion of angiopoietin 2. Atherosclerosis, 327, 87-99. https://doi.org/10.1016/j.atherosclerosis.2021.04.007
Antonopoulos, C. N., Sfyroeras, G. S., Kakisis, J. D., Moulakakis, K. G., & Liapis, C. D. (2014). The role of soluble P selectin in the diagnosis of venous thromboembolism. Thrombosis Research, 133(1), 17-24. https://doi.org/10.1016/j.thromres.2013.08.014
Ministry of Health of Ukraine. (2015, November 2). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) medychnoi dopomohy "Mnozhynna miieloma" [Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care "Multiple myeloma" (No. 710)]. [in Ukrainian]. https://dec.gov.ua/wp-content/uploads/images/dodatki/2015_710_MM/2015_710_YKPMD_MM.pdf
Krasnov, L. A., & Oleinik, V. P. (2014). Monitorirovanie i analiz ritma serdtsa. Tekhnicheskie sredstva elektronnoi i kompyuternoi diagnostiki v meditsine [Monitoring and analysis of heart rhythm. Technical means of electronic and computer diagnostics in medicine]. Kharkov: Natsionalnyi aerokosmichnyi universytet im. M. E. Zhukovskoho "Kharkivskyi aviatsiinii instytut". [in Russian].
Tseluyko, V. Y., & Radchenko, O. V. (2018). Serdechno-sosudistyie zabolevaniya u onkologicheskih bolnyih [Cardiovascular disease in oncological patients]. Liky Ukrainy, (3), 7-20. [in Russian]. https://doi.org/10.37987/1997-9894.2018.3(219)
Chirinos, J. A., Orlenko, A., Zhao, L., Basso, M. D., Cvijic, M. E., Li, Z., Spires, T. E., Yarde, M., Wang, Z., Seiffert, D. A., Prenner, S., Zamani, P., Bhattacharya, P., Kumar, A., Margulies, K. B., Car, B. D., Gordon, D. A., Moore, J. H., & Cappola, T. P. (2020). Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology, 75(11), 1281-1295. https://doi.org/10.1016/j.jacc.2019.12.069
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
